Compare BVS & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BVS | CLLS |
|---|---|---|
| Founded | 2011 | 1999 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 508.4M | 485.6M |
| IPO Year | 2021 | 2007 |
| Metric | BVS | CLLS |
|---|---|---|
| Price | $7.40 | $4.71 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $13.50 | $8.50 |
| AVG Volume (30 Days) | ★ 277.3K | 112.6K |
| Earning Date | 11-04-2025 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.15 | N/A |
| Revenue | ★ $563,829,000.00 | $82,551,000.00 |
| Revenue This Year | N/A | $32.58 |
| Revenue Next Year | $7.11 | $20.68 |
| P/E Ratio | $48.57 | ★ N/A |
| Revenue Growth | 1.58 | ★ 129.04 |
| 52 Week Low | $5.81 | $1.10 |
| 52 Week High | $11.25 | $5.48 |
| Indicator | BVS | CLLS |
|---|---|---|
| Relative Strength Index (RSI) | 50.09 | 54.48 |
| Support Level | $7.26 | $4.47 |
| Resistance Level | $7.71 | $5.03 |
| Average True Range (ATR) | 0.26 | 0.28 |
| MACD | -0.02 | -0.02 |
| Stochastic Oscillator | 44.75 | 54.55 |
Bioventus Inc is a medical technology company. The company is engaged in developing and commercializing clinically differentiated treatments that engage and enhance the body's natural healing process. It offers a diverse portfolio of products to serve physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine and neurosurgery. Its portfolio of products is grouped into three verticals based on clinical use: Pain Treatments, Surgical Solutions, and Restorative Therapies. Geographical presence is in the United States which derives key revenue, and International markets.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.